Also, recent clinical trials and studies on AD have reported on topical JAK inhibitors such as ruxolitinib (JAK1/2) and delgocitinib (pan-JAK), as well as oral JAK inhibitors like baricitinib (JAK1/2) and upadacitinib (JAK-1 selective), suggesting the potential of JAK inhibitors as next-generation targeted therapies for AD [12,14]. Here, JAK1 is linked to Alzheimer disease.